Advertisement

Apoptosis

, Volume 24, Issue 5–6, pp 404–413 | Cite as

Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent

  • Mark A. MilesEmail author
  • Michael A. Harris
  • Christine J. Hawkins
Short Communication
  • 151 Downloads

Abstract

Genotoxic anti-cancer therapies such as chemotherapy and radiotherapy can contribute to an increase in second malignancies in cancer survivors due to their oncogenic effects on non-cancerous cells. Inhibition of histone deacetylase (HDAC) proteins or the proteasome differ from chemotherapy in that they eliminate cancer cells by regulating gene expression or cellular protein equilibrium, respectively. As members of these drug classes have been approved for clinical use in recent times, we investigated whether these two drug classes exhibit similar mutagenic capabilities as chemotherapy. The HDAC inhibitors vorinostat/SAHA and romidepsin/FK288 were found to induce DNA damage, and mis-repair of this damage manifested into mutations in clonogenically viable surviving cells. DNA damage and mutations were also detected in cells treated with the proteasome inhibitor bortezomib. Exposure to both drug classes stimulated caspase activation consistent with apoptotic cell death. Inhibition of caspases protected cells from bortezomib-induced acute (but not clonogenic) death and mutagenesis, implying caspases were required for the mutagenic action of bortezomib. This was also observed for second generation proteasome inhibitors. Cells deficient in caspase-activated DNase (CAD) also failed to acquire DNA damage or mutations following treatment with bortezomib. Surprisingly, vorinostat and romidepsin maintained an equivalent level of killing and mutagenic ability regardless of caspase or CAD activity. Our findings indicate that both drug classes harbour mutagenic potential in vitro. If recapitulated in vivo, the mutagenicity of these agents may influence the treatment of cancer patients who are more susceptible to oncogenic mutations due to dysfunctional DNA repair pathways.

Keywords

Genotoxicity HDAC inhibitors Proteasome inhibitors Second malignant neoplasms Bortezomib Vorinostat 

Notes

Acknowledgements

This study was funded by a Cancer Council Victoria Postdoctoral Fellowship to M.A.M, Research Training Program Scholarship to M.A.H, a grant from The Kids’ Cancer Project and a Grant-in-Aid from the Cancer Council Victoria (Grant No. 1145995).

Compliance with ethical standard

Conflict of interests

The authors declare that they have no conflict of interest.

References

  1. 1.
    Robison LL, Hudson MM (2014) Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 14(1):61–70.  https://doi.org/10.1038/nrc3634 CrossRefGoogle Scholar
  2. 2.
    Bhatia S (2013) Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 40(6):666–675CrossRefGoogle Scholar
  3. 3.
    Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7(5):1016–1036Google Scholar
  4. 4.
    Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL, Neglia JP (2010) Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 102(14):1083–1095CrossRefGoogle Scholar
  5. 5.
    Dai Y, Grant S (2007) Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 67(7):2908–2911CrossRefGoogle Scholar
  6. 6.
    Mannhold R, Fulda S, Carosati E (2010) IAP antagonists: promising candidates for cancer therapy. Drug Discov Today 15(5–6):210–219CrossRefGoogle Scholar
  7. 7.
    Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7):1414CrossRefGoogle Scholar
  8. 8.
    Manasanch EE, Orlowski RZ (2017) Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14(7):417–433CrossRefGoogle Scholar
  9. 9.
    Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942):834–840CrossRefGoogle Scholar
  10. 10.
    Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7):1414CrossRefGoogle Scholar
  11. 11.
    Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 6(10):a026831CrossRefGoogle Scholar
  12. 12.
    Suraweera A, O’Byrne KJ, Richard DJ (2018) Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol 8:92CrossRefGoogle Scholar
  13. 13.
    Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615–2622Google Scholar
  14. 14.
    Okazuka K, Ishida T (2018) Proteasome inhibitors for multiple myeloma. Jpn J Clin Oncol 48(9):785–793CrossRefGoogle Scholar
  15. 15.
    Wang H, Zhou W, Zheng Z, Zhang P, Tu B, He Q, Zhu WG (2012) The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Rep 11(2):146–156CrossRefGoogle Scholar
  16. 16.
    Petruccelli LA, Dupéré-Richer D, Pettersson F, Retrouvey H, Skoulikas S, Miller WH Jr (2011) Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS ONE 6(6):e20987–e20987CrossRefGoogle Scholar
  17. 17.
    Namdar M, Perez G, Ngo L, Marks PA (2010) Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 107(46):20003–20008CrossRefGoogle Scholar
  18. 18.
    Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107(33):14639–14644CrossRefGoogle Scholar
  19. 19.
    Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98(19):10833–10838CrossRefGoogle Scholar
  20. 20.
    Olaharski AJ, Ji Z, Woo JY, Lim S, Hubbard AE, Zhang L, Smith MT (2006) The histone deacetylase inhibitor Trichostatin A has genotoxic effects in human lymphoblasts in vitro. Toxic Sci 93(2):341–347CrossRefGoogle Scholar
  21. 21.
    Roos WP, Krumm A (2016) The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. Nucleic Acids Res 44(21):10017–10030Google Scholar
  22. 22.
    Lioni M, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, Herlyn M, Smalley KSM (2008) Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther 7(9):2866–2875CrossRefGoogle Scholar
  23. 23.
    Palanca A, Casafont I, Berciano MT, Lafarga M (2014) Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol Life Sci 71(10):1961–1975CrossRefGoogle Scholar
  24. 24.
    Stout JT, Caskey CT (1985) HPRT: gene structure, expression, and mutation. Annu Rev Genet 19:127–148CrossRefGoogle Scholar
  25. 25.
    Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M (1999) Risk of leukemia after platinum-based chemotherapy for ovarian cancer. New Eng J Med 340(5):351–357CrossRefGoogle Scholar
  26. 26.
    Was H, Krol SK, Rotili D, Mai A, Wojtas B, Kaminska B, Maleszewska M (2019) Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells. Clin Epigenetics 11(1):11CrossRefGoogle Scholar
  27. 27.
    Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS (2016) Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget 7(39):63829–63838CrossRefGoogle Scholar
  28. 28.
    Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, Hodges E, Vermeer M, Packham G (2011) The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 162(7):1590–1602CrossRefGoogle Scholar
  29. 29.
    Miles MA, Hawkins CJ (2017) Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine. Cell Death Dis 8(10):e3062CrossRefGoogle Scholar
  30. 30.
    Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10(11):3839–3852CrossRefGoogle Scholar
  31. 31.
    Kisselev AF, Goldberg AL (2005) Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 398:364–378CrossRefGoogle Scholar
  32. 32.
    Sun S, Han Y, Liu J, Fang Y, Tian Y, Zhou J, Ma D, Wu P (2014) Trichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells. PLoS ONE 9(3):e91610CrossRefGoogle Scholar
  33. 33.
    Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK (2013) Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS ONE 8(4):e61524–e61524CrossRefGoogle Scholar
  34. 34.
    Robert C, Rassool FV (2012) HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116:87–129CrossRefGoogle Scholar
  35. 35.
    Brodska B, Holoubek A (2011) Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. Oxid Med Cell Longev 2011:253529CrossRefGoogle Scholar
  36. 36.
    Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A (2009) Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 8(11):3075–3087CrossRefGoogle Scholar
  37. 37.
    Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L, Lin J, Hoti N, Nortier JW, DeWeese TL, Hammers H, Carducci MA (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 5(6):e11208CrossRefGoogle Scholar
  38. 38.
    Luo Y, Wang H, Zhao X, Dong C, Zhang F, Guo G, Guo G, Wang X, Powell SN, Feng Z (2016) Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway. Toxicol Res 5(3):859–870CrossRefGoogle Scholar
  39. 39.
    Ladd B, Ackroyd JJ, Hicks JK, Canman CE, Flanagan SA, Shewach DS (2013) Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity. DNA Repair 12(12):1114–1121CrossRefGoogle Scholar
  40. 40.
    Miles MA, Hawkins CJ (2018) Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways. Sci Rep 8(1):14421CrossRefGoogle Scholar
  41. 41.
    Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, Aladjem MI, Pommier Y (2010) Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 70(11):4470–4480CrossRefGoogle Scholar
  42. 42.
    Goodarzi AA, Noon AT, Deckbar D, Ziv Y, Shiloh Y, Lobrich M, Jeggo PA (2008) ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell 31(2):167–177CrossRefGoogle Scholar
  43. 43.
    Liber HL, Thilly WG (1982) Mutation assay at the thymidine kinase locus in diploid human lymphoblasts. Mutat Res 94(2):467–485CrossRefGoogle Scholar
  44. 44.
    Diserens AC, de Tribolet N, Martin-Achard A, Gaide AC, Schnegg JF, Carrel S (1981) Characterization of an established human malignant glioma cell line: LN-18. Acta Neuropathol 53(1):21–28CrossRefGoogle Scholar
  45. 45.
    Shekhar TM, Miles MA, Gupte A, Taylor S, Tascone B, Walkley CR, Hawkins CJ (2016) IAP antagonists sensitize murine osteosarcoma cells to killing by TNFalpha. Oncotarget 7(23):33866–33886CrossRefGoogle Scholar
  46. 46.
    Shekhar TM, Green MM, Rayner DM, Miles MA, Cutts SM, Hawkins CJ (2015) Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells. Mutat Res 777:23–32CrossRefGoogle Scholar
  47. 47.
    Beaumont TE, Shekhar TM, Kaur L, Pantaki-Eimany D, Kvansakul M, Hawkins CJ (2013) Yeast techniques for modeling drugs targeting Bcl-2 and caspase family members. Cell Death Dis 4(5):e619CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mark A. Miles
    • 1
    Email author
  • Michael A. Harris
    • 1
  • Christine J. Hawkins
    • 1
  1. 1.Department of Biochemistry and Genetics, La Trobe Institute for Molecular ScienceLa Trobe UniversityMelbourneAustralia

Personalised recommendations